BioSpace News Archive

2019 Annual General Meeting, which was held on December 5, 2019, in Hong Kong S.A.R., China.

LD Micro 12th Annual Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, California on Wednesday, December 11, at 1:20 pm PT.

CVS Health Corporation announced it has successfully completed the first year of combined operations following the acquisition of Aetna in late 2018.

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered into a definitive merger agreement to acquire Aevi Genomic Medicine

New Structure and Tautomer Handling Routines Aim to Improve Data Integrity in Drug Discovery

FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of overactive bladder (OAB) in women, announces that it has completed an equity financing round the proceeds of which will allow the Company to accelerate development of its second-generation system through regulatory clearance in the U.S. Participants

On July 1, 2019, the Company received a written notification from the Nasdaq Listing Qualifications Staff indicating that the Company did not comply with the annual meeting requirement for continued listing on The Nasdaq Capital Market set forth in Listing Rule 5620

Medical Marijuana, Inc. (“the Company”) (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that subsidiary HempMeds® Brasil applauds ANVISA (the National Agency for Health Supervision) for unanimously approving the regulation of medical marijuana to be sold at pharmacies and drugstores nationwide

For the third quarter of 2019, PANTHERx obtained the highest Net Promoter Score (NPS) among all specialty pharmacies surveyed including retail, hospital/health system, PBM/payer, and independent specialty pharmacies.

Neurelis’ investigational product candidate, VALTOCO® (diazepam nasal spray), currently under review by the U.S. Food and Drug Administration